EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Azole‐Resistant Aspergillosis: An Emerging Diagnostic and Therapeutic Challenge in Paediatrics

Natalia Mendoza-Palomar iD, Carlos Grasa Lozano iD, Begoña Carazo-Gallego iD, Elena María Rincón-López iD, Maria Pinyol-Sarrias iD, Anna Creus-Costa iD, Ana Méndez-Echevarría iD, Alfredo Maldonado-Barrueco iD, Yasmina Mozo iD, Diego Lozano-Durán, Maria Luisa Navarro Gómez iD, Jesús Guinea iD und 3 weitere

Mycoses · 2026-11 · 69 (11)

DOI: 10.1111/myc.70206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycoses, online erschienen am 29.10.2026. Verfasst von Natalia Mendoza-Palomar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall D'hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain. Hauptthemen laut MEDLINE: Antifungal Agents, Azoles, Drug Resistance, Fungal, Aspergillosis. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Invasive aspergillosis (IA) represents one of the most frequent invasive fungal infections in paediatric patients with risk factors. An increase in cases of azole‐resistant IA has been reported in adult patients. The aim of this study is to present a series of 11 cases of paediatric patients with this pathology.

Methods

A retrospective descriptive study including paediatric patients with probable or proven azole‐resistant IA treated between January 2019 and June 2024 in four tertiary hospitals in Spain.

Results

Eleven cases are reported, all patients with risk factors for IA, mainly with haematopoietic stem cell transplantation (HCT) due to haematological malignancies and heart transplant in the early post‐transplant period. These patients represent 22% of all proven or probable paediatric IA cases ( n = 50) diagnosed in the study centres during the period. Five were previously receiving azole‐based antifungal prophylaxis. The most frequently isolated species was Aspergillus fumigatus . Despite receiving at least partially active antifungals plus adjunctive treatment therapy from diagnosis, attributable mortality was high (8/11 patients).

Conclusion

Azole‐resistant IA should be suspected in paediatric patients with risk factors, especially if they show poor clinical course or have received azole prophylaxis. The performance of invasive tests, as well as species identification and resistance testing, is essential to optimise treatment. In breakthrough IA it should be considered empirical treatment with an antifungal from a different class than the one used for prophylaxis, alone or in combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsAzolesDrug Resistance, FungalAspergillosisHumansRetrospective StudiesFemaleMaleChildSpainChild, PreschoolAspergillus fumigatusRisk FactorsAdolescentHematopoietic Stem Cell TransplantationInfant

Stichwörter der Autor:innen

fungal drug resistanceinvasive pulmonary aspergillosispaediatrics

Substanzen

Antifungal AgentsAzoles

Autor:innen und Institutionen

  • Paediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall D'hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
  • Infection and Immunity in Children, Vall D'hebron Institut de Recerca (VHIR), Vall D'hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Paediatric Infectious Diseases Department, Hospital Universitario La Paz (Madrid), Madrid, Spain.
  • Instituto de Investigación del Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.
  • Centro de Investigacion en Red en Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Paediatric Infectious Diseases and Immunodeficiencies, Málaga Regional University Hospital, Málaga, Spain.

ORCID-Profile: Natalia Mendoza-Palomar, Carlos Grasa Lozano, Begoña Carazo-Gallego, Elena María Rincón-López, Maria Pinyol-Sarrias, Anna Creus-Costa, Ana Méndez-Echevarría, Alfredo Maldonado-Barrueco, Yasmina Mozo, Maria Luisa Navarro Gómez, Jesús Guinea, Maria Concepción Mediavilla Gradolph, Pere Soler-Palacín, María Teresa Martín-Gómez

Förderung

  • Gilead Sciences

Zitieren

APA

Mendoza-Palomar, N., Grasa Lozano, C., Carazo-Gallego, B., Rincón-López, E. M., Pinyol-Sarrias, M., Creus-Costa, A., Méndez-Echevarría, A., Maldonado-Barrueco, A., Mozo, Y., Lozano-Durán, D., Navarro Gómez, M. L., Guinea, J., Mediavilla Gradolph, M. C., Soler-Palacín, P., & Martín-Gómez, M. T. (2026). Azole‐Resistant Aspergillosis: An Emerging Diagnostic and Therapeutic Challenge in Paediatrics. Mycoses, 69(11). https://doi.org/10.1111/myc.70206

Vancouver

Mendoza-Palomar N, Grasa Lozano C, Carazo-Gallego B, Rincón-López EM, Pinyol-Sarrias M, Creus-Costa A, et al. Azole‐Resistant Aspergillosis: An Emerging Diagnostic and Therapeutic Challenge in Paediatrics. Mycoses. 2026;69(11). doi:10.1111/myc.70206

BibTeX
@article{MendozaPalomar2026,
  author = {Mendoza-Palomar, Natalia and Grasa Lozano, Carlos and Carazo-Gallego, Begoña and Rincón-López, Elena María and Pinyol-Sarrias, Maria and Creus-Costa, Anna and Méndez-Echevarría, Ana and Maldonado-Barrueco, Alfredo and Mozo, Yasmina and Lozano-Durán, Diego and Navarro Gómez, Maria Luisa and Guinea, Jesús and Mediavilla Gradolph, Maria Concepción and Soler-Palacín, Pere and Martín-Gómez, María Teresa},
  title = {Azole‐Resistant Aspergillosis: An Emerging Diagnostic and Therapeutic Challenge in Paediatrics},
  journal = {Mycoses},
  year = {2026},
  volume = {69},
  number = {11},
  doi = {10.1111/myc.70206}
}
Kostenlos starten →